Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Releases Guidance Documents On PMA, 510(k) Review Times And Goals

This article was originally published in The Gray Sheet

Executive Summary

The agency outlined how it plans to calculate review times and meet performance goals for PMA and 510(k) submissions in two recent guidance documents.

You may also be interested in...



FDA Outlines Mandated eCopy Submission Program In Draft Guidance

The agency issued a draft guidance listing the requirements for its eCopy submission program for medical devices. An eCopy will be mandatory for all device firms after the draft is finalized.

Final FDA Bill: Device Provisions

Congress has settled on final language for the FDA Safety and Innovation Act. After Senate approval, the bill will go to the White House for President Obama’s signature.

Device Industry Expects Quicker Path To Market In Exchange For Doubling Of User Fees

The tentative agreement of $595 million in user fees over five years is more than companies had wanted to spend. But industry negotiators insist it is a good deal, tied to performance goals and process improvements they say will ensure greater speed and predictability in reaching the U.S. market.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT031667

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel